HOST Therabiomics Wants to Develop Dietary Compound into Bowel-disease Treatment

HOST Therabiomics Wants to Develop Dietary Compound into Bowel-disease Treatment
HOST Therabiomics hopes to develop the dietary compound HOST-G904, which improved the composition of gut bacteria without increasing gas, into a treatment for inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and other gut conditions. The company published a study of the investigational prebiotic's impact on gut bacteria, “Metabolic adaptation of colonic microbiota to galactooligosaccharides: a proof-of-concept-study,” in the journal Alimentary Pharmacology and Therapeutics. “These results show the potential for HOST-G904 to improve the gastrointestinal microbiome without causing discomforting gastrointestinal symptoms often associated with other treatments for functional gut disorders," Graham Waters, HOST Therabiomics' CEO, said in a press release. “HOST-G904 is designed to optimize the gut microbiome and support the immune system's defenses against certain diseases, and may offer new hope for patients impacted by IBS, IBD and other gut disorders. Based on these positive results, HOST Therabiomics will further analyze this compound in a Phase 2b study.” Many patients with gut conditions are urged to stick to a diet referred to as FODMAP, for fermentable oligosaccharides, disaccharides, monosaccharides and polyols. The diet limits sugars, lactose and other compounds believed to contribute to gut symptom
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *